67872 Federal Register / Vol. 62, No. 249 / Tuesday, December 30, 1997 / Notices

violate Section 7 of the Clayton Act and

Section 5 of the Federal Trade

Commission Act. I find reason to believe

that the joint venture, if consummated,

would affect competition adversely in

the refining of asphalt in Northern

California and, therefore, support

Paragraph VII of the order, which

provides relief in that market. I do not

find reason to believe the other

violations of law alleged in the

complaint and, therefore, dissent from

Paragraphs II, III, IV and V of the order,

which require divestitures in other

markets. Although the allegation

relating to refineries in the northwestern

United States is arguably valid, on

balance, I cannot support it and,

therefore, cannot support Paragraph II of

the order. The complaint allegations

that support Paragraphs III, IV and V of

the order seem to me far removed from

our usual analysis under the merger

guidelines.

I understand that the parties have

negotiated identical relief with various

state attorneys general and that the

divestitures in the proposed

Commission order will be required in

any event. My obligation, however, is to

apply federal law as I see it.

[FR Doc. 97–33872 Filed 12–29–97; 8:45 am]

BILLING CODE 6750–01–M

GENERAL ACCOUNTING OFFICE

Federal Accounting Standards

Advisory Board

AGENCY: General Accounting Office.

ACTION: Notice of January meeting.

SUMMARY: Pursuant to section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. No. 92–463), as amended,

notice is hereby given that the Federal

Accounting Standards Advisory Board

will hold a two day meeting on

Thursday and Friday, January 22 and

23, 1998, from 9:00 A.M. to 4:00 P.M.

in Room 7C13 of the General

Accounting Office building, 441 G St.,

N.W., Washington, D.C.

The purpose of the meeting is to

discuss the following issues: (1)

Accounting for Loans and Loan

Guarantees; (2) Accounting for Property

and Plant Equipment; (3) Accounting for

Social Insurance; and (4) the addition of

new projects for 1998.

Any interested person may attend the

meeting as an observer. Board

discussions and reviews are open to the

public.

FOR FURTHER INFORMATION CONTACT:

Wendy Comes, Executive Director, 441

G St., N.W., Room 3B18, Washington,

D.C. 20548, or call (202) 512–7350.

Authority: Federal Advisory Committee

Act. Pub. L. No. 92–463, Section 10(a)(2), 86

Stat. 770, 774 (1972) (current version at 5

U.S.C. app. section 10(a)(2) (1988); 41 CFR

101–6.1015 (1990).

Dated: December 23, 1997.

Wendy M. Comes,

Executive Director.

[FR Doc. 97–33938 Filed 12–29–97; 8:45 am]

BILLING CODE 1610–01–M

GENERAL SERVICES

ADMINISTRATION

[OMB Control No. 3090–0040]

Proposed Collection; Comment

Request Entitled Application for

Shipping Instructions and Notice of

Availability

AGENCY: Federal Supply Service, GSA.

ACTION: Notice of request for public

comments regarding reinstatement to a

previously approved OMB clearance

(3090–0040).

SUMMARY: Under the provisions of the

Paperwork Reduction Act of 1995 (44

U.S.C. Chapter 35), the Office of

Acquisition Policy has submitted to the

Office of Management and Budget

(OMB) a request to review and approve

a reinstatement of a previously

approved information collection

requirement concerning Application for

Shipping Instructions and Notice of

Availability.

DATES: Comment Due Date: March 2,

1998.

ADDRESSES: Comments regarding this

burden estimate or any other aspect of

this collection of information, including

suggestions for reducing this burden,

should be submitted to: Edward

Springer, GSA Desk Officer, Room 3235,

NEOB, Washington, DC 20503, and to

Marjorie Ashby, General Services

Administration (MVP), 1800 F Street

NW, Washington, DC 20405.

FOR FURTHER INFORMATION CONTACT:

Marcia Crockett, Acquisition Operations

& Electronic Commerce Center, Supply

Management Division, (703) 305–7551.

SUPPLEMENTARY INFORMATION:

A. Purpose

The GSA is requesting the Office of

Management and Budget (OMB) to

reinstate information collection, 3090–

0400, concerning Application for

Shipping Instructions and Notice of

Availability. This information collection

supports and justifies the markup of the

six percent surcharge for the GSA export

reimbursable program. It also is used to

evaluate and obtain the best cube

utilization of shipping vans and

containers for export direct delivery

shipments. The form contains data

necessary to prepare Transportation

Control and Movement Documents

(TCMD) which are required when

material enters the Defense

Transportation System.

B. Annual Reporting Burden

Respondents: 500; annual responses:

4,000; average hours per response: .20;

burden hours: 1,333.

COPY OF PROPOSAL: A copy of this

proposal may be obtained from the GSA

Acquisition Policy Division (MVP),

Room 4011, GSA Building, 1800 F

Street NW, Washington, DC 20405, or by

telephoning (202) 501–3822, or by

faxing your request to (202) 501–3341.

Dated: December 19, 1997.

Ida M. Ustad,

Deputy Associate Administrator, Office of

Acquisition Policy.

[FR Doc. 97–33905 Filed 12–29–97; 8:45 am]

BILLING CODE 6820–61–M

GENERAL SERVICES

ADMINISTRATION

Federal Supply Service; Broker and

Direct Move Management Services

Provider Participation in the General

Services Administration’s Centralized

Household Goods Traffic Management

Program (CHAMP)

AGENCY: Federal Supply Service, GSA.

ACTION: Notice of proposed program

changes for comment: Extension of

comment period.

SUMMARY: This document extends the

comment period of the document

published at 62 FR 64225, December 4,

1997, to January 12, 1998. Earlier this

year, GSA provided the household

goods transportation industry an

opportunity to comment on its draft

1997 Household Goods Tender of

Service (HTOS). GSA has received and

reviewed the industry’s comments on

the draft 1997 HTOS and is in the

process of making appropriate revisions

to the document before issuing it in

final. The provisions contained in this

notice apply to household goods

transportation broker and direct move

management services provider

participants in CHAMP and were not

included in the original draft HTOS. We

are offering these provisions for

industry review and comment at this

time.

DATES: Please submit your comments by

January 12, 1998.

ADDRESSES: Mail comments to the

Travel and Transportation Management
Federal Register / Vol. 62, No. 249 / Tuesday, December 30, 1997 / Notices 67873

Staff (FBX), General Services

Administration, Washington, DC 20406.

Attn: Federal Register Notice. GSA will

consider your comments in developing

the final move management services

provisions. In the interim, rates filed in

response to GSA’s 1996 Request for

Offers have been extended for 90 days

from October 31, 1997 to January 29,

1998.

FOR FURTHER INFORMATION CONTACT:

Larry Tucker, Senior Program Analyst,

Travel and Transportation Management

Staff, FSS/GSA, 703–305–7660.

SUPPLEMENTARY INFORMATION: The

proposed changes appear at 62 FR

64225, December 4, 1997.

Dated: December 22, 1997.

Janice Sandwen,

Director, Travel and Transportation

Management Staff.

[FR Doc. 97–33862 Filed 12–29–97; 8:45 am]

BILLING CODE 6820–24–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Notice of Three Meetings of the

National Bioethics Advisory

Commission (NBAC) and its

Subcommittees

SUMMARY: Pursuant to Section 10(d) of

the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is given of three meetings of the

National Bioethics Advisory

Commission and its subcommittees. The

Commission will continue addressing

the protection of the rights and welfare

of human subjects in research including

decisionally impaired populations and

the federal agency survey as well as

issues in genetics including genetics

information and tissue storage. The

meetings are open to the public and

opportunities for statements by the

public will be provided.

Dates, Times, and Locations

Genetics Subcommittee: January 6,

1998, 1:30 pm–5:00 pm, Crystal

Gateway Marriott Hotel, 1700

Jefferson Davis Highway, Arlington,

Virginia

Full Commission: January 7, 1998, 8:00

am–5:00 pm, Crystal Gateway

Marriott Hotel, 1700 Jefferson Davis

Highway, Arlington, Virginia

Human Subjects Subcommittee: January

8, 1998, 8:00 am—12:30 pm, Crystal

Gateway Marriott Hotel, 1700

Jefferson Davis Highway, Arlington,

Virginia

SUPPLEMENTARY INFORMATION: The

President established the National

Bioethics Advisory Commission (NBAC)

by Executive Order 12975 on October 3,

1995. The mission of the NBAC is to

advise and make recommendations to

the National Science and Technology

Council and other entities on bioethical

issues arising from the research on

human biology and behavior, and in the

applications of that research including

clinical applications.

Public Participation

The meetings are open to the public

with attendance limited by the

availability of space. Members of the

public who wish to present oral

statements should contact Ms. Patricia

Norris by telephone, fax machine, or

mail as shown below prior to the

meeting as soon as possible. The Chairs

of the full Commission and

subcommittees will reserve time for

presentations by persons requesting to

speak. The order of speakers will be

assigned on a first come, first serve

basis. Individuals unable to make oral

presentations are encouraged to mail or

fax their comments to the NBAC staff

office at least four business days prior

to the meeting for distribution to the

subcommittee members or Commission

and inclusion in the public record.

Persons needing special assistance, such

as sign language interpretation or other

special accommodations, should contact

NBAC staff at the address or telephone

number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms.

Patricia Norris, National Bioethics

Advisory Commission, MSC–7508, 6100

Executive Boulevard, Suite 5B01,

Rockville, Maryland 20892–7508,

telephone 301–402–4242, fax number

301–480–6900.

Henrietta D. Hyatt-Knorr,

Deputy Executive Director, National Bioethics

Advisory Commission.

[FR Doc. 97–33792 Filed 12–29–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Orphan Products Board; Notice of

Public Meeting

AGENCY: Office of Public Health and

Science.

ACTION: Notice of meeting.

SUMMARY: The Department of Health and

Human Services and the Office of Public

Health and Science (Office of the

Assistant Secretary for Health) are

announcing a public meeting of the

Orphan Products Board. The purpose of

this meeting is to facilitate the research,

development, and approval of orphan

products and to coordinate Government

activities with the private sector to

achieve these goals. In this meeting

there will be an opportunity for

interested persons to present

information and views on the issue of

orphan products development.

DATES: The public meeting be held on

Thursday, February 12, 1998, from 2

p.m. to 5 p.m. Requests to attend or

participate should be sent by February

4, 1998.

ADDRESSES: The public meeting will be

held at the Hubert H. Humphrey Bldg.,

200 Independence Ave. S.W.,

Washington, DC. Written requests to

attend or participate should be sent to

Robert F. Steeves, Orphan Products

Board, Food and Drug Administration

(HF–35), 5600 Fishers Lane, rm. 8–73,

Rockville, MD 20857, FAX 301–443–

4915. Requests from nongovernmental

persons should include full name,

address, affiliation, and social security

number for use in obtaining security

clearance for entry into the facility.

FOR FURTHER INFORMATION CONTACT:

Robert F. Steeves, Orphan Products

Board, Food and Drug Administration

(HF–35), 5600 Fishers Lane, Rockville,

MD 20857, 301–827–3666.

SUPPLEMENTARY INFORMATION: An orphan

drug is a drug for the treatment of a rare

disease or condition which either has:

(1) A prevalence in the United States of

under 200,000 persons; or (2) a higher

prevalence and for which there is no

reasonable expectation that the cost of

developing and making available in the

United States a drug for such disease or

condition will be recovered from sales

in the United States of such drug. The

Orphan Drug Act (Pub. L. 97–414)

enacted on January 4, 1983, as amended,

established a number of incentives to

encourage the development and

marketing of orphan drugs.

The Orphan Drug Act also established

an Orphan Products Board to promote

the development of drugs and devices

for rare diseases or conditions and to

assure appropriate coordination among

interested Federal agencies,

manufacturers, and organizations

representing patients with rare diseases.

The Orphan Products Board is chaired

by the Assistant Secretary for Health.

The Board is composed of

representatives from the Department of

Health and Human Services (DHHS), the

Department of Veterans Affairs (DVA),

The National Institute of Disability and

Rehabilitation Research (NIDRR), the

Social Security Administration (SSA),

and the Department of Defense (DOD).

Within DHHS, representatives from the